| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VACCINE.2004.11.064 |
| P698 | PubMed publication ID | 15780738 |
| P50 | author | Jun Zhang | Q56256577 |
| P2093 | author name string | Mun H Ng | |
| Guo Y Huang | |||
| Ning S Xia | |||
| Shan H Ou | |||
| Shao W Li | |||
| Sheng X Ge | |||
| Shu Q Pang | |||
| Yang L Xian | |||
| Yi M Li | |||
| Zhi Q He | |||
| P2860 | cites work | Hepatitis E virus. | Q53862581 |
| Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. | Q53961708 | ||
| Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine | Q73389272 | ||
| Properties and classification of hepatitis A virus | Q30834425 | ||
| The effectiveness and safety of hepatitis A vaccine: a systematic review | Q35126721 | ||
| Successful passive and active immunization of cynomolgus monkeys against hepatitis E | Q35838428 | ||
| Expression and self-assembly of empty virus-like particles of hepatitis E virus | Q35894748 | ||
| Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. | Q38329067 | ||
| Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells | Q42061077 | ||
| A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus | Q43631931 | ||
| Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis | Q45091646 | ||
| Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model. | Q45710834 | ||
| Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus | Q45733752 | ||
| Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis E virus structural protein | Q45737295 | ||
| Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. | Q52598828 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| hepatitis E | Q326643 | ||
| P304 | page(s) | 2893-2901 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates | |
| P478 | volume | 23 |
| Q37502688 | A dual vaccine candidate against norovirus and hepatitis E virus |
| Q36845713 | A high-throughput neutralizing assay for antibodies and sera against hepatitis E virus |
| Q41178447 | A novel linear neutralizing epitope of hepatitis E virus |
| Q37197088 | A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions |
| Q40585281 | A shared N-terminal hydrophobic tail for the formation of nanoparticulates |
| Q36519453 | A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus |
| Q35331616 | A valuable antigen detection method for diagnosis of acute hepatitis E. |
| Q92879574 | Animal Models for Hepatitis E virus |
| Q36973372 | Antigenic determinants of hepatitis E virus and vaccine-induced immunogenicity and efficacy. |
| Q38580913 | Antigenic properties of avian hepatitis E virus capsid protein. |
| Q36245120 | Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs |
| Q37630325 | Autochthonous hepatitis e virus infections: a new transfusion-associated risk? |
| Q42222473 | Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes |
| Q83026182 | Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes |
| Q40507463 | Characteristics and Functions of HEV Proteins |
| Q52579744 | Characterization of Three Novel Linear Neutralizing B-Cell Epitopes in the Capsid Protein of Swine Hepatitis E Virus. |
| Q36134262 | Characterization of the Specificity, Functionality, and Durability of Host T-Cell Responses Against the Full-Length Hepatitis E Virus |
| Q28830058 | Chemically activatable viral capsid functionalized for cancer targeting |
| Q92511096 | Chicken Organic Anion-Transporting Polypeptide 1A2, a Novel Avian Hepatitis E Virus (HEV) ORF2-Interacting Protein, Is Involved in Avian HEV Infection |
| Q43168143 | Classification of human and zoonotic group hepatitis E virus (HEV) using antigen detection |
| Q45387631 | Clinical significance of anti-HEV IgA in diagnosis of acute genotype 4 hepatitis E virus infection negative for anti-HEV IgM. |
| Q59352246 | Cloning and expression of truncated ORF2 as a vaccine candidate against hepatitis E virus |
| Q35887653 | Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment |
| Q26782030 | Current Knowledge on Hepatitis E |
| Q35189231 | Detection of serum antibodies to hepatitis E virus in domestic pigs in Italy using a recombinant swine HEV capsid protein |
| Q36914794 | Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus |
| Q40589840 | Development and validation of a new serum standard for the measurement of anti-HEV antibodies in animals |
| Q27656916 | Dimerization of Hepatitis E Virus Capsid Protein E2s Domain Is Essential for Virus–Host Interaction |
| Q40302625 | Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine |
| Q42616164 | Effector T cells immune reactivity among patients with acute hepatitis E. |
| Q45029264 | Effects of mRNA secondary structure on the expression of HEV ORF2 proteins in Escherichia coli |
| Q45189946 | Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial |
| Q35683323 | Enhanced humoral response in pregnant mice immunized with liposome encapsulated recombinant neutralizing epitope protein of Hepatitis- E virus |
| Q35391544 | Enhanced mucosal immune responses induced by a combined candidate mucosal vaccine based on Hepatitis A virus and Hepatitis E virus structural proteins linked to tuftsin |
| Q28072683 | Epidemiology of Hepatitis E in Pregnant Women and Children in Iran: A General Overview |
| Q40507459 | Epidemiology of Hepatitis E. |
| Q38076254 | Epidemiology of mammalian hepatitis E virus infection |
| Q89965385 | Expression, Purification and Characterization of the Hepatitis E Virus Like-Particles in the Pichia pastoris |
| Q45324780 | Generation in yeast and antigenic characterization of hepatitis E virus capsid protein virus-like particles. |
| Q34151626 | HEV-Capsid Protein Interacts With Cytochrome P4502C8 and Retinol-Binding Protein 4. |
| Q42640194 | Hepatitis A and E: update on prevention and epidemiology |
| Q56656388 | Hepatitis E |
| Q92376567 | Hepatitis E Virus Drug Development |
| Q37278231 | Hepatitis E vaccine |
| Q54334450 | Hepatitis E vaccine development: a 14 year odyssey. |
| Q41089524 | Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission |
| Q40118705 | Hepatitis E virus ORF 1 induces proliferative and functional T-cell responses in patients with ongoing and resolved hepatitis E. |
| Q26751267 | Hepatitis E virus as an emerging zoonotic pathogen |
| Q36678270 | Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts |
| Q38917141 | Hepatitis E virus enters liver cells through a dynamin-2, clathrin and membrane cholesterol-dependent pathway |
| Q37544935 | Hepatitis E virus infection |
| Q37473517 | Hepatitis E virus infections in humans and animals |
| Q37375936 | Hepatitis E virus: Current epidemiology and vaccine |
| Q38014371 | Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity |
| Q38379216 | Hepatitis E: A disease of reemerging importance |
| Q37320904 | Hepatitis E: an emerging infection in developed countries. |
| Q50524547 | Hepatitis E: are psychiatric patients on special risk? |
| Q38137898 | Hepatitis E: current status. |
| Q38839954 | Hepatitis E: latest developments in knowledge. |
| Q37613164 | Hepatitis e: molecular virology and pathogenesis |
| Q37544940 | Host immune status and response to hepatitis E virus infection. |
| Q35532771 | Identification of Broad-Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-Neutralizing Antibody |
| Q47561286 | Immunity against hepatitis E virus infection: Implications for therapy and vaccine development |
| Q52659699 | Immunization against Hepatitis E. |
| Q40507436 | Immunobiology and Host Response to HEV. |
| Q36256455 | Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice |
| Q40507410 | Laboratory Diagnosis of HEV Infection |
| Q27013018 | Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins |
| Q59349514 | Life cycle and morphogenesis of the hepatitis E virus |
| Q37103536 | Macaque models of human infectious disease |
| Q37534616 | Management of hepatitis E virus (HEV) zoonotic transmission: protection of rabbits against HEV challenge following immunization with HEV 239 vaccine |
| Q43326979 | Maternal transfer of antibodies to the offspring after mice immunization with insect larvae-derived recombinant hepatitis E virus ORF-2 proteins. |
| Q40781273 | Modeling the long-term antibody response of a hepatitis E vaccine. |
| Q28066101 | Molecular Biology and Infection of Hepatitis E Virus |
| Q34166393 | Molecular virology of hepatitis E virus |
| Q58618417 | Multifaceted characterization of recombinant protein-based vaccines: An immunochemical toolbox for epitope-specific analyses of the hepatitis E vaccine |
| Q58696384 | N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro |
| Q54229856 | Nonhuman Primate Models of Hepatitis A Virus and Hepatitis E Virus Infections. |
| Q59350268 | Nonhuman primate models of human viral infections |
| Q37854151 | Pathogenetic elements of hepatitis E and animal models of HEV infection |
| Q39804868 | Prevention of hepatitis E: another step forward |
| Q40035451 | Production and characterization of a Brazilian candidate antigen for Hepatitis E Virus genotype 3 diagnosis. |
| Q40730375 | Production of Influenza Virus HA1 Harboring Native-Like Epitopes by Pichia pastoris |
| Q40507392 | Prophylactic Hepatitis E Vaccine |
| Q92808828 | Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation |
| Q38699244 | Prophylaxis against hepatitis E: at risk populations and human vaccines. |
| Q45410567 | Protection of chickens against avian hepatitis E virus (avian HEV) infection by immunization with recombinant avian HEV capsid protein |
| Q98245645 | Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans |
| Q21090828 | Rabbit as a novel animal model for hepatitis E virus infection and vaccine evaluation |
| Q83235565 | Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine |
| Q40477519 | Real-time stability of a hepatitis E vaccine (Hecolin®) demonstrated with potency assays and multifaceted physicochemical methods. |
| Q38819439 | Recent advancements in combination subunit vaccine development |
| Q38075857 | Recent advances in molecular medicine techniques for the diagnosis, prevention, and control of infectious diseases |
| Q42212470 | Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®). |
| Q45390634 | Serological and molecular evidence of hepatitis E virus in swine in Brazil. |
| Q37894294 | Serological diagnostics of hepatitis E virus infection |
| Q36023562 | Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China |
| Q35578943 | Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q34464464 | The development of a recombinant hepatitis E vaccine HEV 239. |
| Q34982710 | Three amino acid mutations (F51L, T59A, and S390L) in the capsid protein of the hepatitis E virus collectively contribute to virus attenuation |
| Q28730718 | Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine |
| Q37881208 | Toward the development of a hepatitis E vaccine |
| Q35073715 | Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. |
| Q51784137 | Vaccine Development against Zoonotic Hepatitis E Virus: Open Questions and Remaining Challenges. |
Search more.